The BD Alaris Infusion System’s “One System” platform securely connects all patient modules to provide care teams with a single, comprehensive patient view. Credit: Becton, Dickinson and Company / PRNewswire.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Becton, Dickinson and Company’s (BD) updated BD Alaris Infusion System.

The approval encompasses the latest hardware advancements for point-of-care units (PCU), patient-controlled analgesia (PCA) pumps, large volume pumps, syringe pumps and respiratory monitoring and auto-identification modules.

Related Company Profiles

View all

Furthermore, the clearance covers a new BD Alaris Infusion System software version with improved cybersecurity and interoperability features.

These features facilitate intelligent, connected care with the most used electronic medical record (EMR) systems.

It is claimed to be the only system with a centralised user interface for up to four modules for all major types of infusions.

See Also:

The infusions include syringe pumps, large-volume pumps and PCA therapy with optional respiratory monitoring. One interface controls all modules with a common PCU.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hospitals and health systems can use the comprehensive infusion system for optimising their workflows and easily scaling their infusion requirements across an entire integrated delivery network besides offering interoperability with EMRs.

In addition, the new system can transmit data to the BD HealthSight platform, facilitating comprehensive enterprise medication management.

BD chairman, CEO and president Tom Polen said: “We are deeply committed to ensuring clinicians can continue to rely on our market-leading system to meet today’s most critical infusion needs.

“The features and enhancements incorporated into the updated BD Alaris Infusion System and subject to this clearance reinforce our advancements in smart, connected care, which delivers greater benefit to clinicians and patients and helps improve health care system efficiency through better care coordination and utilisation of actionable information.”